{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:49:00Z","timestamp":1790336940981,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1378\/chest.12-0653","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T09:32:06Z","timestamp":1370511126000},"page":"1282-1290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era"],"prefix":"10.1016","volume":"144","author":[{"given":"Melvyn","family":"Rubenfire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Seibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1378\/chest.12-0653_bib1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1378\/chest.12-0653_bib2","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1378\/chest.12-0653_bib3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/art.24525","article-title":"The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France","volume":"60","author":"Hachulla","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1378\/chest.12-0653_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1378\/chest.12-0653_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1378\/chest.12-0653_bib6","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1378\/chest.12-0653_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1183\/09031936.00081706","article-title":"Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension","volume":"29","author":"Mathai","year":"2007","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1378\/chest.12-0653_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","article-title":"Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1378\/chest.12-0653_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1378\/chest.12-0653_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1378\/chest.12-0653_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1378\/chest.12-0653_bib12","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","article-title":"Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol","volume":"36","author":"Badesch","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1378\/chest.12-0653_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"issue":"16","key":"10.1378\/chest.12-0653_bib14","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.12-0653_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1378\/chest.12-0653_bib16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/ard.2007.077149","article-title":"Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials","volume":"67","author":"Avouac","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1378\/chest.12-0653_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1378\/chest.12-0653_bib18","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"issue":"4","key":"10.1378\/chest.12-0653_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.01.17406470","article-title":"Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension","volume":"17","author":"Paciocco","year":"2001","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1378\/chest.12-0653_bib20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0735-1097(98)00361-1","article-title":"Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine","volume":"32","author":"Ricciardi","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1378\/chest.12-0653_bib21","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1378\/chest.12-0653_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/kep398","article-title":"Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil","volume":"49","author":"Launay","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1378\/chest.12-0653_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/rheumatology\/kep449","article-title":"Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome","volume":"49","author":"Hachulla","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1378\/chest.12-0653_bib24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2009.120303","article-title":"Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group","volume":"69","author":"Avouac","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1378\/chest.12-0653_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1378\/chest.12-0653_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1378\/chest.12-0653_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1378\/chest.12-0653_bib28","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1378\/chest.12-0653_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1378\/chest.12-0653_bib30","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1378\/chest.12-0653_bib31","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.healun.2004.12.113","article-title":"Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases","volume":"24","author":"Girgis","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"10.1378\/chest.12-0653_bib32","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1378\/chest.12-0653_bib33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1378\/chest.12-0653_bib34","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.rmed.2010.03.020","article-title":"Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension","volume":"104","author":"O'Callaghan","year":"2010","journal-title":"Respir Med"},{"issue":"12","key":"10.1378\/chest.12-0653_bib35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1164\/rccm.200909-1331PP","article-title":"Systemic sclerosis-associated pulmonary arterial hypertension","volume":"181","author":"Le Pavec","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1378\/chest.12-0653_bib36","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/art.30423","article-title":"Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies","volume":"63","author":"Le Pavec","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1378\/chest.12-0653_bib37","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival","volume":"63","author":"Humbert","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213606741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213606741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:38:57Z","timestamp":1757918337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369213606741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0012369213606741"],"URL":"https:\/\/doi.org\/10.1378\/chest.12-0653","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718018237.793502292","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718018237.793478148","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.12-0653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}